RxDoctor Payments Data

Damian Ayichi

Psychiatric/Mental Health · Baltimore, MDNPI 1790111532

Payments from drug & device makers

$668in general payments, 2019–2025

Across 25 payments — averaging $26.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$156
  • AbbVie$155
  • Neurocrine Biosciences, Inc.$81
  • Takeda Pharmaceuticals U.S.A., Inc.$70
  • TMS Neurohealth Centers Inc.$55
  • Almatica Pharma LLC$50
  • plus $100 from 5 others

What the payments were for

  • Food & beverage$668100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$668 in reported general payments places this provider in the 60th percentile of 1,461 psychiatric/mental health providers in Maryland.

See all psychiatric/mental health providers in Maryland

Medicare billing

Part B allowed, 2024
$32,718
Medicare patients
32
Services billed
357

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate12$101,609
Divalproex Sodium ErDivalproex Sodium15$1,982
Vilazodone Hcl12$1,901
Bupropion XlBupropion Hcl71$1,611
Clozapine23$1,559
Oxcarbazepine45$1,547
Zolpidem Tartrate ErZolpidem Tartrate12$1,508
Clonazepam78$731
Duloxetine Hcl19$590
Lamotrigine47$526
Lorazepam46$394
Escitalopram Oxalate54$365
Quetiapine Fumarate28$300
Risperidone36$273
Aripiprazole21$247

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$81$101,60912 claims
Almatica Pharma LLCSertraline Hcl$50$22823 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,461 psychiatric/mental health providers in Maryland.

Other psychiatric/mental health in Baltimore

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →